{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=20", "query": { "intervention": "Placebo Once Weekly", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 901, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Once+Weekly&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T19:34:27.025Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02508389", "title": "A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Radiation Induced Oral Mucositis" ], "interventions": [ { "name": "Low Dose GC4419: 30mg/day", "type": "DRUG" }, { "name": "High Dose GC4419: 90mg/day", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Galera Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 223, "start_date": "2015-10-12", "completion_date": "2019-08-29", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 55 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02508389" }, { "nct_id": "NCT02612857", "title": "Trial of IMO-8400 in Adult Patients With Dermatomyositis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatomyositis" ], "interventions": [ { "name": "IMO-8400 Dose Group 1", "type": "DRUG" }, { "name": "IMO-8400 Dose Group 2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idera Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2015-11", "completion_date": "2018-06", "has_results": true, "last_update_posted_date": "2019-10-10", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02612857" }, { "nct_id": "NCT07284875", "title": "Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "Ribupatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kailera", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2530, "start_date": "2025-12-18", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 24, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 21 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284875" }, { "nct_id": "NCT02277769", "title": "Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo (for Dupilumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 708, "start_date": "2014-11-30", "completion_date": "2016-01-31", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 53, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 50 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277769" }, { "nct_id": "NCT01938001", "title": "Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2013-11-21", "completion_date": "2022-01-26", "has_results": true, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 35, "location_summary": "Mobile, Alabama • Glendale, Arizona • Escondido, California + 31 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01938001" }, { "nct_id": "NCT03406377", "title": "Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "OPK-88003", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OPKO Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 113, "start_date": "2018-04-02", "completion_date": "2019-06-27", "has_results": true, "last_update_posted_date": "2021-06-15", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 3, "location_summary": "Huntington Park, California • Los Angeles, California • Hialeah, Florida", "locations": [ { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03406377" }, { "nct_id": "NCT02248701", "title": "Testosterone Plus Finasteride Treatment After Spinal Cord Injury", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Spinal Cord Injury", "Spinal Cord Injuries", "Trauma, Nervous System", "Wounds and Injuries", "Central Nervous System Diseases", "Nervous System Diseases", "Spinal Cord Diseases", "Gonadal Disorders", "Endocrine System Diseases", "Hypogonadism", "Genital Diseases, Male" ], "interventions": [ { "name": "Testosterone Enanthate", "type": "DRUG" }, { "name": "Finasteride", "type": "DRUG" }, { "name": "Placebo injection", "type": "DRUG" }, { "name": "Placebo pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 33, "start_date": "2017-04-27", "completion_date": "2021-08-13", "has_results": true, "last_update_posted_date": "2023-09-29", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 2, "location_summary": "Gainesville, Florida • Tampa, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02248701" }, { "nct_id": "NCT01393405", "title": "Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 179, "start_date": "2012-02", "completion_date": "2017-04", "has_results": true, "last_update_posted_date": "2018-04-17", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 31, "location_summary": "Los Angeles, California • Denver, Colorado • Winter Park, Florida + 26 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393405" }, { "nct_id": "NCT01000623", "title": "Venlafaxine and Hypnosis or Focused Attention in Treating Patients with Hot Flashes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hot Flashes" ], "interventions": [ { "name": "venlafaxine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "hypnotherapy", "type": "PROCEDURE" }, { "name": "mind-body intervention procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 71, "start_date": "2010-01-31", "completion_date": "2015-09-08", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01000623" }, { "nct_id": "NCT05970640", "title": "A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-alcoholic Fatty Liver Disease", "Obesity" ], "interventions": [ { "name": "BI 3006337", "type": "DRUG" }, { "name": "Placebo matching BI 3006337", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 64, "start_date": "2023-08-14", "completion_date": "2024-11-07", "has_results": true, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-11-14T19:34:27.025Z", "location_count": 12, "location_summary": "Chula Vista, California • La Mesa, California • Montclair, California + 8 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05970640" } ] }